Literature DB >> 1548742

trans-dominant inhibition of human immunodeficiency virus type 1 Rev occurs through formation of inactive protein complexes.

T J Hope1, N P Klein, M E Elder, T G Parslow.   

Abstract

The human immunodeficiency virus type 1 Rev protein controls expression of certain viral RNAs by binding to these RNAs in the nucleus. To investigate how dominant negative Rev mutants inhibit Rev function, we fused such mutants to hormone-dependent localization signals from the glucocorticoid receptor. Each was found to have fully potent inhibitory activity whether expressed in the nucleus or in the cytoplasm. Wild-type Rev colocalized with an inhibitory fusion protein, implying that the two proteins interact. The resulting complexes accumulated within nuclei in response to steroids but had no effect on expression of Rev-responsive mRNAs. A mutation known to block in vitro oligomerization of Rev abolished both complex formation and inhibitory activity of the mutant fusion proteins. Thus, trans-dominant inhibition of Rev does not require competition for nuclear substrates but may instead reflect the ability of a mutant to form nonfunctional complexes with the wild-type protein in vivo.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1548742      PMCID: PMC288971     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Interaction of the human immunodeficiency virus type 1 Rev protein with a structured region in env mRNA is dependent on multimer formation mediated through a basic stretch of amino acids.

Authors:  H S Olsen; A W Cochrane; P J Dillon; C M Nalin; C A Rosen
Journal:  Genes Dev       Date:  1990-08       Impact factor: 11.361

2.  Characterization of HIV-1 REV protein: binding stoichiometry and minimal RNA substrate.

Authors:  K S Cook; G J Fisk; J Hauber; N Usman; T J Daly; J R Rusche
Journal:  Nucleic Acids Res       Date:  1991-04-11       Impact factor: 16.971

3.  Structure-function analyses of the HTLV-I Rex and HIV-1 Rev RNA response elements: insights into the mechanism of Rex and Rev action.

Authors:  Y F Ahmed; S M Hanly; M H Malim; B R Cullen; W C Greene
Journal:  Genes Dev       Date:  1990-06       Impact factor: 11.361

4.  Structural and functional characterization of the human immunodeficiency virus rev protein.

Authors:  A Perkins; A W Cochrane; S M Ruben; C A Rosen
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

5.  HIV-1 regulator of virion expression (Rev) protein binds to an RNA stem-loop structure located within the Rev response element region.

Authors:  S Heaphy; C Dingwall; I Ernberg; M J Gait; S M Green; J Karn; A D Lowe; M Singh; M A Skinner
Journal:  Cell       Date:  1990-02-23       Impact factor: 41.582

Review 6.  Human immunodeficiency virus as a prototypic complex retrovirus.

Authors:  B R Cullen
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

7.  Sequence-specific RNA binding by the HIV-1 Rev protein.

Authors:  M L Zapp; M R Green
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

Review 8.  Functional inactivation of genes by dominant negative mutations.

Authors:  I Herskowitz
Journal:  Nature       Date:  1987 Sep 17-23       Impact factor: 49.962

9.  HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA.

Authors:  M B Feinberg; R F Jarrett; A Aldovini; R C Gallo; F Wong-Staal
Journal:  Cell       Date:  1986-09-12       Impact factor: 41.582

10.  Purification and characterization of recombinant Rev protein of human immunodeficiency virus type 1.

Authors:  C M Nalin; R D Purcell; D Antelman; D Mueller; L Tomchak; B Wegrzynski; E McCarney; V Toome; R Kramer; M C Hsu
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

View more
  35 in total

1.  Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.

Authors:  M R Mautino; N Keiser; R A Morgan
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Polyvalent Rev decoys act as artificial Rev-responsive elements.

Authors:  T L Symensma; S Baskerville; A Yan; A D Ellington
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

3.  CRM1-dependent function of a cis-acting RNA export element.

Authors:  Ileana Popa; Matthew E Harris; John E Donello; Thomas J Hope
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

4.  Human immunodeficiency virus type 1 Rev activation can be achieved without Rev-responsive element RNA if Rev is directed to the target as a Rev/MS2 fusion protein which tethers the MS2 operator RNA.

Authors:  S Venkatesan; S M Gerstberger; H Park; S M Holland; Y Nam
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

5.  New approach for inhibiting Rev function and HIV-1 production using the influenza virus NS1 protein.

Authors:  X Y Qian; Z Y Chen; J Zhang; A B Rabson; R M Krug
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

Review 6.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

7.  Molding a peptide into an RNA site by in vivo peptide evolution.

Authors:  K Harada; S S Martin; R Tan; A D Frankel
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

8.  Trans-dominant inhibitory human immunodeficiency virus type 1 protease monomers prevent protease activation and virion maturation.

Authors:  L M Babé; J Rosé; C S Craik
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

9.  Cellular protein modulates effects of human immunodeficiency virus type 1 Rev.

Authors:  Y Luo; H Yu; B M Peterlin
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

10.  Effects of translation initiation factor eIF-5A on the functioning of human T-cell leukemia virus type I Rex and human immunodeficiency virus Rev inhibited trans dominantly by a Rex mutant deficient in RNA binding.

Authors:  J Katahira; T Ishizaki; H Sakai; A Adachi; K Yamamoto; H Shida
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.